<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and treatment of premenopausal osteoporosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and treatment of premenopausal osteoporosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and treatment of premenopausal osteoporosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carolyn B Becker, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adi Cohen, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Few data exist to guide clinical care for premenopausal women who have low bone mineral density (BMD; Z-score ≤-2.0) and/or a history of fragility fractures. The guidelines for the treatment of osteoporosis based on BMD in postmenopausal women do not generally apply to premenopausal women, as the relationship between bone mass and fracture differs in these two populations. In premenopausal women, the term osteoporosis is reserved for patients who present with low trauma/fragility fracture(s) or for those with low BMD and high risk of further short-term bone loss and fracture. Low BMD alone should not be used to define osteoporosis in a premenopausal woman but, like fragility fracture, is an indication for further evaluation.</p><p>This topic reviews the evaluation and treatment of premenopausal osteoporosis. The epidemiology and etiology of premenopausal osteoporosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Bone mineral density (BMD) screening is not routinely recommended for premenopausal women [<a href="#rid1">1</a>].</p><p>We agree with the International Society of Clinical Densitometry (ISCD) guidelines that suggest BMD screening for premenopausal women under the following circumstances [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of a fragility fracture</p><p class="bulletIndent1"><span class="glyph">●</span>Known secondary causes of osteoporosis  (<a class="graphic graphic_table graphicRef64403" href="/z/d/graphic/64403.html" rel="external">table 1</a>)</p><p></p><p>Routine BMD screening of pre- or perimenopausal women is not recommended. Some studies have shown beneficial changes in behavior when BMD testing is combined with education about bone health [<a href="#rid2">2,3</a>], but routine BMD testing in these populations has not been shown to reduce fracture risk. As an example, in one study of 669 premenopausal women (3.8 percent with fractures), osteoporosis education coupled with BMD testing resulted in positive lifestyle changes [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3786829564"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low BMD for chronologic age</strong> – Premenopausal women with low bone mineral density (BMD) Z-score (≤-2.0) but no history of fragility fracture have low BMD for chronologic age. The term osteoporosis should not be used in this setting, because the relationship between low BMD and fracture risk is unknown for this population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoporosis</strong> – Premenopausal women with a history of low trauma fracture(s) should have a diagnosis of osteoporosis irrespective of BMD. A diagnosis of osteoporosis also may be made in premenopausal women with low BMD and an active condition or medication exposure (eg, celiac disease, anorexia nervosa or other cause of malnutrition, glucocorticoid therapy) that is known to confer high risk of further bone loss or fracture in the short term.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cause</strong> – A primary cause of osteoporosis is a genetic or developmental bone disorder that leads to bone fragility. Examples of known primary genetic causes include osteogenesis imperfecta (OI), Ehlers Danlos syndrome, and osteoporosis pseudoglioma syndrome. (See <a class="local">'Evaluation'</a> below and <a class="local">'Primary cause identified'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary cause</strong> – Most premenopausal women with low BMD or osteoporosis have an identifiable secondary cause of bone loss  (<a class="graphic graphic_table graphicRef64403" href="/z/d/graphic/64403.html" rel="external">table 1</a>) [<a href="#rid4">4,5</a>]. Secondary causes comprise any acquired, underlying condition or medication exposure that contributes to bone loss or fragility. Identification of a contributing condition often helps guide management of the affected individual. (See <a class="local">'Evaluation'</a> below and <a class="local">'Secondary cause identified'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic low BMD and osteoporosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low BMD</strong> – Premenopausal women with low BMD (Z-score ≤-2.0) but no history of fragility fracture and no known primary or secondary causes of bone loss (after extensive evaluation) have idiopathic low BMD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osteoporosis</strong> – Premenopausal women with low trauma fracture(s) and no identifiable etiology of bone loss after extensive evaluation for primary and secondary causes have idiopathic osteoporosis.</p><p></p><p class="bulletIndent1">Premenopausal patients with idiopathic low BMD or osteoporosis may have had a transient, secondary cause that led to prior bone loss or attainment of suboptimal peak bone mass. Premenopausal women with idiopathic osteoporosis alternatively may have an unknown primary cause of osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk for ongoing bone loss or fracture</strong> – Some secondary causes of low BMD or osteoporosis confer high risk of bone loss or fracture, often in part due to suppression of ovarian function with consequent estradiol deficiency.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – Premenopausal women taking glucocorticoids are at high risk for bone loss, although the associated risk for fracture in this population has not been well defined. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Premenopausal women and younger men'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy</strong> – Chemotherapy-induced hypogonadism and glucocorticoids are the principal causes of low BMD in women undergoing cancer treatment, and both can cause rapid bone loss. (See  <a class="medical medical_review" href="/z/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer", section on 'Chemotherapy-induced amenorrhea'</a> and  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1776365994"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>Premenopausal women who come to medical attention because of a fragility fracture or detection of low bone mineral density (BMD; Z-score ≤-2.0) should undergo evaluation to identify potential primary and secondary causes of bone loss. Premenopausal women with a history of fragility fracture require evaluation for underlying causes of osteoporosis even in the absence of low BMD. Women with a known primary or secondary cause of bone loss or fragility should undergo evaluation to identify additional contributory causes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the initial evaluation</strong> – The initial evaluation entails a history, physical examination, and biochemical testing with the goal of identifying any primary and secondary causes of bone loss or fragility. Many secondary causes can be assessed solely through a careful history and physical examination  (<a class="graphic graphic_table graphicRef64403" href="/z/d/graphic/64403.html" rel="external">table 1</a>). Clinical history should include age of menarche, history of oligo- or amenorrhea, prior pregnancy and lactation, dietary and exercise patterns, tobacco and alcohol use, and medications. We also ask about gastrointestinal symptoms, kidney stone history, surgical history, and family history of osteoporosis and fracture.</p><p></p><p class="bulletIndent1">Laboratory evaluation may help diagnose secondary causes of osteoporosis, such as kidney or liver disease, hyperthyroidism, hyperparathyroidism, Cushing syndrome or subclinical hypercortisolism, early menopause, celiac disease and other forms of malabsorption, idiopathic hypercalciuria, or inflammatory arthritis. For women with a history of fragility fracture, non-osteoporosis causes of bone fragility (eg, osteomalacia and other mineralization disorders), and pathologic fracture should also be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial laboratory tests</strong> – For all premenopausal women with low BMD and/or fragility fracture, we obtain the following basic tests  (<a class="graphic graphic_table graphicRef53634" href="/z/d/graphic/53634.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count</p><p class="bulletIndent2"><span class="glyph">•</span>Serum calcium, phosphate, and creatinine levels</p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests (alkaline phosphatase and aminotransferase levels)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum 25-hydroxyvitamin D level</p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid-stimulating hormone (TSH) level</p><p class="bulletIndent2"><span class="glyph">•</span>24-hour urine collection for calcium and creatinine measurement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – In the setting of unusual fracture(s) (eg, atypical site or type for osteoporotic fracture; antecedent, localized bone pain), imaging or other evaluation should also be performed to assess for pathologic fracture related to underlying malignancy or other bone lesion. (See  <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">"Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis", section on 'Clinical presentation'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Additional laboratory tests</span><span class="headingEndMark"> — </span>Women who have abnormalities on initial laboratory testing, suspicious findings on history and physical examination, or unexplained osteoporosis and fracture after the initial evaluation require additional laboratory tests  (<a class="graphic graphic_table graphicRef53634" href="/z/d/graphic/53634.html" rel="external">table 2</a>). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Women with anemia, low urinary calcium excretion, and/or low vitamin D levels should be evaluated for celiac disease and other etiologies of malabsorption. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Metabolic bone disorders'</a> and  <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with hyper- or hypocalcemia, hyper- or hypocalciuria, or a history of kidney stones, serum parathyroid hormone (PTH) levels should be measured. (See  <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">"Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with signs or symptoms suggestive of hypercortisolism, measurement of 24-hour urinary free cortisol or other testing for Cushing syndrome should be conducted. (See  <a class="medical medical_review" href="/z/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Bone loss'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In women with oligo- or amenorrhea in whom pregnancy and hyperprolactinemia have been excluded, we measure serum estradiol and gonadotropin levels. (See  <a class="medical medical_review" href="/z/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea", section on 'Initial evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H816763077"><span class="h2">Nonpharmacologic approaches for all women</span><span class="headingEndMark"> — </span>All women with low bone mineral density (BMD) or osteoporosis should undertake nonpharmacologic strategies for preserving bone mass including sufficient intake of calcium and vitamin D. Additional, nonpharmacologic strategies for reducing risk of further bone loss include regular weightbearing exercise and physical activity [<a href="#rid6">6</a>], cessation of smoking [<a href="#rid7">7,8</a>], avoidance of undernutrition and wide fluctuations in body weight [<a href="#rid9">9</a>], and moderation in alcohol consumption [<a href="#rid10">10</a>].</p><p>In general, lifestyle modifications should be encouraged for all women with low bone mass since these help preserve bone mass, and it may be possible to have small increases in bone mass even in the fourth decade of life [<a href="#rid11">11-13</a>]. An observational study of 16 premenopausal women with idiopathic osteoporosis (mean age 35.7 years) treated with increased dietary calcium, vitamin D, and physical activity demonstrated significant increases in BMD at the lumbar spine and femoral neck after two and three years, respectively [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H277456492"><span class="h3">Calcium and vitamin D intake</span><span class="headingEndMark"> — </span>For women without a history of kidney stones, nonpharmacologic interventions include adequate calcium (1000 mg total from diet plus supplements if needed) and vitamin D (600 international units <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">vitamin D3</a> daily) intake [<a href="#rid15">15-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p>For women with a history of kidney stones, additional evaluation (eg, measurement of 24-hour urinary calcium excretion, serum calcium and parathyroid hormone [PTH] levels) is required before making supplementation recommendations. Specific recommendations for calcium intake in women with a history of kidney stones are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones", section on 'Maintain adequate calcium intake'</a>.)</p><p class="headingAnchor" id="H1842267809"><span class="h3">Intensity of exercise</span><span class="headingEndMark"> — </span>Studies support a benefit of physical activity, including jumping, high impact, and resistance exercises for BMD in premenopausal women [<a href="#rid6">6,19,20</a>]. However, excessive exercise in premenopausal women may lead to weight loss and/or hypothalamic amenorrhea, exacerbating low BMD. Therefore, women should be counseled to adjust both exercise intensity and total physical activity as needed to ensure maintenance of a healthy body weight. (See  <a class="medical medical_review" href="/z/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/z/d/html/14705.html" rel="external">"Anorexia nervosa in adults and adolescents: Medical complications and their management", section on 'Endocrine'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Exercise'</a>.)</p><p class="headingAnchor" id="H90673111"><span class="h2">Primary cause identified</span><span class="headingEndMark"> — </span>When a primary cause of bone loss or fragility is identified, management is determined by the underlying diagnosis. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteogenesis imperfecta in</strong> <strong>adults</strong> – Osteogenesis imperfecta (OI) is a heterogeneous disorder with widely variable disease severity. Although most affected patients are diagnosed in childhood, fractures leading to diagnosis of OI can occur in young adulthood. Fewer data are available to guide treatment of OI in adults than in children. Studies have been small and, thus, do not definitively address fracture endpoints [<a href="#rid21">21-23</a>]. The diagnosis and treatment of OI are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2943.html" rel="external">"Osteogenesis imperfecta: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypophosphatasia in adults</strong> – Hypophosphatasia is an inborn error of metabolism due to mutation of the gene encoding tissue nonspecific alkaline phosphatase. It is a very heterogeneous disorder with widely variable disease severity. In adults, hypophosphatasia can present as osteomalacia, chondrocalcinosis, and/or stress fractures [<a href="#rid24">24</a>]. Treatment is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults", section on 'Other causes'</a>.)</p><p></p><p class="headingAnchor" id="H2758466606"><span class="h2">Secondary cause identified</span><span class="headingEndMark"> — </span>When a secondary cause of bone loss is identified, interventions should be targeted to address the specific cause with subsequent monitoring for improvement.</p><p class="headingAnchor" id="H1612863303"><span class="h3">Treat the underlying cause</span><span class="headingEndMark"> — </span>In cases where a secondary cause is found, treatment should first be targeted to that specific disease or abnormality. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease and other malabsorptive disorders</strong> – Eliminating gluten from the diet of young women diagnosed with celiac disease leads to improvement in BMD [<a href="#rid25">25-29</a>]. Premenopausal women with other malabsorptive conditions (eg, inflammatory bowel disease, post-metabolic surgery) are at risk of bone loss due to underweight or significant body weight loss, nutrient and vitamin deficiencies, and/or hypogonadism that frequently results from nutritional stress. Treatment of the underlying condition helps mitigate bone loss. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Metabolic bone disorders'</a> and  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/587.html" rel="external">"Bariatric surgery: Postoperative nutritional management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hyperparathyroidism</strong> – Parathyroidectomy in premenopausal women with primary hyperparathyroidism results in improvement in BMD. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Subclinical bone disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic hypercalciuria</strong> – Premenopausal women with idiopathic hypercalciuria can be treated with a thiazide diuretic and low sodium diet to prevent excess calcium loss. (See  <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones", section on 'High urine calcium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medroxyprogesterone acetate</strong> – Women with bone loss due to depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> have improvement in BMD upon discontinuation of the drug [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estradiol</strong><strong> deficiency</strong> – In women with hypogonadism from various causes, treatment should be directed at the underlying cause. If resumption of menses is unlikely, we provide treatment for hypogonadism unless clear contraindications exist. The time frame and specific recommendations for initiating treatment vary with the cause of hypogonadism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anorexia nervosa</strong> – Nutritional recovery and resumption of normal menstrual function appear necessary for skeletal recovery in patients with anorexia nervosa. Data suggest that transdermal <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> may improve or preserve bone mass in some patients with anorexia nervosa [<a href="#rid32">32</a>]. Management of hypogonadism due to anorexia nervosa is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86685.html" rel="external">"Anorexia nervosa: Endocrine complications and their management", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy for non-hormone-dependent cancer</strong> – In premenopausal women with amenorrhea or early menopause due to chemotherapy, treatment of hypogonadism is usually warranted in the absence of contraindications. (See  <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Functional hypothalamic amenorrhea, primary ovarian insufficiency, and other causes</strong> – The treatment of functional hypothalamic amenorrhea and primary ovarian insufficiency is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/110816.html" rel="external">"Functional hypothalamic amenorrhea: Evaluation and management", section on 'Estrogen replacement'</a> and  <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent2">Treatment of hypogonadism significantly reduces bone loss when given to women with oligo- or amenorrhea, women with endometriosis or fibroids on gonadotropin-releasing hormone (GnRH) receptor analog therapy [<a href="#rid33">33,34</a>], or women experiencing perimenopausal bone loss [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'GnRH with add-back therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7428.html" rel="external">"Menopausal hormone therapy in the prevention and treatment of osteoporosis", section on 'Efficacy of estrogen therapy'</a>.)</p><p></p><p class="headingAnchor" id="H3351433512"><span class="h3">Indications for concomitant pharmacologic treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe fracture history</strong> – For women with a history of<strong> </strong>fracture at major sites (eg, spine or hip) or multiple fragility fractures, we suggest pharmacologic therapy in addition to treating any underlying causes of bone loss. Clinical data to guide treatment decisions for premenopausal women with severe fracture history are scarce. Our suggestions are based on clinical experience, small clinical trials, and indirect evidence from trial data in postmenopausal women. (See <a class="local">'Choice of therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk for short-term bone loss</strong> – For women with advanced bone loss and/or fragility fracture, concomitant pharmacologic treatment also may be warranted when an active secondary cause cannot be readily mitigated and confers high risk for additional short-term bone loss. (See <a class="local">'Choice of therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid therapy</strong> – Premenopausal women taking glucocorticoids for a variety of inflammatory or autoimmune conditions present a special therapeutic challenge. Fracture risk in premenopausal women taking glucocorticoids is not clearly defined, and the potential pregnancy-related risks of pharmacologic therapy are unique to premenopausal women. The prevention and treatment of glucocorticoid-induced osteoporosis in premenopausal women is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Premenopausal women and younger men'</a> and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemotherapy</strong> – Special consideration is needed in patients with estrogen-dependent cancers who also may be treated with additional therapies that adversely affect BMD. (See <a class="local">'Nonpharmacologic approaches for all women'</a> above and  <a class="medical medical_review" href="/z/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Amenorrhea or early menopause</strong> – In premenopausal women with a hormone-dependent cancer who have low BMD (Z-score ≤-2.0 or T-score ≤-2.5) and/or fragility fracture <strong>and</strong> develop amenorrhea or early menopause due to chemotherapy, we usually initiate pharmacologic therapy. (See <a class="local">'Choice of therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a>.)</p><p></p><p class="bulletIndent3">In premenopausal women undergoing chemotherapy for breast cancer, the incidence and reversibility of chemotherapy-induced amenorrhea depends on the drugs used  (<a class="graphic graphic_table graphicRef51143" href="/z/d/graphic/51143.html" rel="external">table 3</a>). Chemotherapy-induced amenorrhea is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/745.html" rel="external">"Overview of side effects of chemotherapy for early-stage breast cancer", section on 'Chemotherapy-induced amenorrhea'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Tamoxifen</strong><strong> therapy</strong> – In contrast to its bone protective effects in postmenopausal and amenorrheic women [<a href="#rid36">36,37</a>], <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> can contribute to bone loss in premenopausal women with normal ovarian function. For premenopausal women with low BMD who maintain normal menstrual cycles while taking tamoxifen, we monitor BMD and usually defer pharmacologic therapy except for women with a history of fragility fracture, very low BMD (Z-score ≤-3.0), and/or evidence of accelerated bone loss (≥4 to 5 percent BMD loss per year). (See  <a class="medical medical_review" href="/z/d/html/2068.html" rel="external">"Selective estrogen receptor modulators for prevention and treatment of osteoporosis", section on 'Tamoxifen'</a>.)</p><p></p><p class="bulletIndent3">In a population cohort study comparing 1761 premenopausal women with breast cancer with an age-matched control group of 1761 women without breast cancer, fracture risk was significantly higher in women with breast cancer who received <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> than in controls [<a href="#rid38">38</a>]. In a prospective study with three years of follow-up, women treated with tamoxifen who continued to menstruate following chemotherapy lost 4.6 percent of lumbar spine BMD, while BMD in those who did not receive tamoxifen remained stable [<a href="#rid39">39</a>]. Tamoxifen-treated women who became amenorrheic after chemotherapy lost less bone at the lumbar spine than women with amenorrhea who did not receive tamoxifen, but both groups had significant declines in BMD (6.8 percent loss with tamoxifen compared with 9.5 percent loss in nontreated women).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Aromatase inhibitor therapy</strong> – Aromatase inhibitors (AIs) are used in women with estrogen receptor-positive breast cancer and cause significant bone loss and increased risk of fracture. AI-induced bone loss and its management are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a>.)</p><p></p><p class="headingAnchor" id="H2293702497"><span class="h3">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment with concomitant pharmacologic therapy</strong> – After initiation of pharmacologic therapy in high-risk individuals, we remeasure BMD in one year. The details of pharmacologic treatment monitoring and duration of therapy are reviewed in detail separately for bisphosphonates and <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>. (See  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Monitoring response to therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Practical management issues'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Duration of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of secondary cause(s) only</strong> – If pharmacologic therapy is not initiated, we remeasure BMD in one to two years after intervention to address the secondary cause of bone loss. We reserve pharmacotherapy for selected women with persistently high risk of bone loss or fracture after treating the secondary cause or when the secondary cause cannot be adequately mitigated. (See <a class="local">'Pharmacologic therapy for selected women'</a> below.)</p><p></p><p class="bulletIndent1">Specifically, pharmacologic treatment is usually warranted if any of the following develop:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interim fragility fracture</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of accelerated, ongoing bone loss (≥4 to 5 percent BMD loss per year)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very low BMD (eg, Z-score ≤-3.0) <strong>and</strong> the secondary cause is ongoing or cannot be adequately addressed</p><p></p><p class="headingAnchor" id="H1899627982"><span class="h2">Idiopathic low BMD or osteoporosis</span><span class="headingEndMark"> — </span>All women with low bone mineral density (BMD) or osteoporosis without a clear primary or secondary cause should undertake nonpharmacologic strategies to prevent further bone loss. (See <a class="local">'Nonpharmacologic approaches for all women'</a> above.)</p><p class="headingAnchor" id="H1734728725"><span class="h3">Low BMD for age</span><span class="headingEndMark"> — </span>In premenopausal women with low bone mineral density (BMD) alone (ie, without history of fractures or known secondary causes for low BMD), pharmacotherapy is generally not indicated. After completing an evaluation for secondary causes, it is reasonable to ensure adequate calcium intake and vitamin D sufficiency and repeat BMD measurement in one to two years. (See <a class="local">'Nonpharmacologic approaches for all women'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable BMD on repeat measurement</strong> – For women with idiopathic low BMD who have stable BMD on repeat measurement, we continue nonpharmacologic interventions. We remeasure BMD at least once more in two years to ensure stability. Low bone mass in premenopausal women may be due to failure to attain expected peak bone mass or previous bone loss due to a secondary cause that has resolved. For example, some women may have genetically determined low peak bone mass. Other women may have accrued less bone than expected due to insults to the skeleton (eg, medications, poor nutrition, estrogen deficiency) that occurred during adolescence or early adulthood and are no longer present at the time of evaluation. In either case, these women are expected to have stable BMD, even though BMD is low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence of ongoing bone loss</strong> – Idiopathic low BMD with evidence of ongoing bone loss is rare and often reflects an ongoing secondary cause or an undiagnosed primary cause. Ongoing bone loss should always prompt additional evaluation for potential secondary causes  (<a class="graphic graphic_table graphicRef64403" href="/z/d/graphic/64403.html" rel="external">table 1</a>). Bone loss in the context of very low BMD (eg, Z-score ≤-3.0) may warrant pharmacologic treatment. Women with idiopathic low BMD and ongoing bone loss should be referred to a metabolic bone specialist whenever possible for further evaluation and management.</p><p></p><p class="headingAnchor" id="H1169135483"><span class="h3">History of fragility fracture</span><span class="headingEndMark"> — </span>Idiopathic osteoporosis (ie, fragility fracture irrespective of BMD and without known primary or secondary cause[s]) is rare. Childhood fractures (early onset) and family history are often reported in this setting, suggesting an underlying genetic etiology [<a href="#rid40">40-42</a>]. Some genetic etiologies may affect bone formation processes leading to low peak bone mass whereas others (eg, those associated with hypercalciuria) may contribute to bone loss. Idiopathic hypercalciuria has been observed in a substantial proportion of women identified as having idiopathic osteoporosis [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2058.html" rel="external">"Epidemiology and etiology of premenopausal osteoporosis", section on 'Etiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Women who meet criteria for</strong> <strong>pharmacologic therapy</strong> – Clinical data to guide treatment decisions for premenopausal women with idiopathic osteoporosis are scarce. In the absence of strong clinical evidence, we suggest pharmacologic therapy for selected premenopausal women with a history of fragility fracture in the following circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fragility fracture at a major site (eg, spine, hip)</p><p class="bulletIndent2"><span class="glyph">•</span>Other fracture (eg, wrist) with very low BMD (Z-score ≤-3.0)</p><p class="bulletIndent2"><span class="glyph">•</span>History of multiple fragility fractures</p><p></p><p class="bulletIndent1">For women with idiopathic osteoporosis who begin pharmacologic therapy, we remeasure BMD in one year. The details of pharmacologic treatment monitoring and duration of therapy are reviewed in detail separately for bisphosphonates and <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>. (See  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Monitoring response to therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Practical management issues'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Duration of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Women who do not meet criteria for pharmacologic therapy</strong> – For women with idiopathic osteoporosis who do not meet criteria for pharmacologic therapy, we implement nonpharmacologic interventions and remeasure BMD in one year. For these women, a single low BMD measurement can reflect issues affecting skeletal development or attainment of peak bone mass and does not by itself signify a process of bone loss. In such cases, serial BMD assessments are necessary to document BMD trajectory.</p><p></p><p class="bulletIndent1">Bone turnover markers are of limited utility and should be interpreted with caution, as the reference ranges are wide in premenopausal women [<a href="#rid43">43</a>]. Additionally, markers of bone resorption must be interpreted according to the patient's age; adolescence and young adulthood are characterized by active bone modeling and physiologic increases in markers of bone turnover. Elevated bone turnover markers also are expected after a recent fracture. (See  <a class="medical medical_review" href="/z/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption"</a> and  <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">"Bone physiology and biochemical markers of bone turnover"</a> and  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable BMD on repeat measurement</strong> – For women with idiopathic osteoporosis who have stable BMD on repeat measurement, we continue nonpharmacologic interventions. We remeasure BMD at least once more in two years to ensure stability. (See <a class="local">'Nonpharmacologic approaches for all women'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evidence of ongoing bone loss</strong> – Idiopathic osteoporosis with evidence of ongoing bone loss is rare and often reflects an ongoing secondary cause or an undiagnosed primary cause. Women with idiopathic osteoporosis who have evidence of ongoing bone loss should undergo additional evaluation for potential secondary causes  (<a class="graphic graphic_table graphicRef64403" href="/z/d/graphic/64403.html" rel="external">table 1</a>). Bone loss in the context of a history of fragility fracture should prompt referral to a metabolic bone specialist whenever possible. In this setting, pharmacologic therapy is usually warranted. (See <a class="local">'Choice of therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H3507220751"><span class="h2">Pharmacologic therapy for selected women</span></p><p class="headingAnchor" id="H1851515518"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>For most women who meet criteria for pharmacologic therapy, we prefer antiresorptive therapy with bisphosphonates [<a href="#rid44">44-53</a>]. We opt for initial anabolic therapy (eg, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>) prior to bisphosphonate therapy for selected women with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>History of vertebral or other major (eg, hip) fracture(s).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very low BMD (Z-score ≤-3.0) with a history of fragility fracture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Known or presumed primary osteoporosis with history of fragility fracture (in whom BMD is often stable, reducing the potential benefit of antiresorptive therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desire for pregnancy in the short term – For women who meet criteria for pharmacologic treatment and desire future pregnancy in the short term, we also may opt for an initial course of anabolic therapy.</p><p></p><p>Pharmacologic therapies that have shown antifracture efficacy in <strong>postmenopausal</strong> women include bisphosphonates, selective estrogen receptor modulators (SERMs), <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>, <a class="drug drug_general" data-topicid="112992" href="/z/d/drug information/112992.html" rel="external">abaloparatide</a>, <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, and <a class="drug drug_general" data-topicid="120976" href="/z/d/drug information/120976.html" rel="external">romosozumab</a>. However, very few data are available to guide clinicians in the use of these medications in <strong>premenopausal</strong> women.</p><p class="headingAnchor" id="H4287832983"><span class="h3">Antiresorptive therapy with bisphosphonates</span><span class="headingEndMark"> — </span>We use bisphosphonate therapy (<a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a>) for most premenopausal women with osteoporosis who warrant pharmacologic therapy. There are few randomized, controlled trials of antiresorptive therapy in premenopausal women with osteoporosis. Studies demonstrating the benefits of bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis included some premenopausal women. As a result, both alendronate and risedronate are approved in the United States and other countries for use in women receiving glucocorticoids. The dosing and administration of bisphosphonates are the same as in postmenopausal women. This topic is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations</strong> – Although bisphosphonates have been shown to prevent bone loss in young women with various conditions [<a href="#rid44">44-53</a>], long-term efficacy, safety, and fracture data are scarce in premenopausal women. The decision to initiate treatment with bisphosphonates in any premenopausal woman should be made on a case-by-case basis with consideration of individual fracture risk and potential medication effects. In general, the goal should be for the shortest possible duration of bisphosphonate use, particularly in light of data regarding rare potential risks of long-term use, such as osteonecrosis of the jaw (ONJ) [<a href="#rid54">54,55</a>] and atypical femoral fractures [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Risks specific to oral bisphosphonates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use during preconception and pregnancy</strong> – Given the long half-life of bisphosphonates in bone, these agents should be used with caution in reproductive-age women [<a href="#rid56">56-58</a>]. In an experimental rat model, bisphosphonates crossed the placenta and accumulated in fetal bones [<a href="#rid59">59,60</a>]. Most case reports of bisphosphonate use during pregnancy do not report adverse maternal or fetal outcomes [<a href="#rid53">53,61-64</a>]. In one larger case-control study including 36 women exposed to bisphosphonates, no major teratogenic effects were reported, but there was an increased frequency of nonspecific neonatal complications among women who had underlying, systemic disease [<a href="#rid65">65</a>]. Two women with OI treated with long-term intravenous (IV) <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> prior to conception had normal pregnancies and deliveries, but mild neonatal abnormalities occurred (transient hypocalcemia in one neonate and bilateral talipes equinovarus in the other) [<a href="#rid66">66</a>].</p><p></p><p class="headingAnchor" id="H771293421"><span class="h3">Anabolic therapy with teriparatide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> (parathyroid hormone [PTH] 1-34) stimulates bone formation as well as resorption, but intermittent administration stimulates bone formation more than resorption, thus benefitting patients with osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p>Subcutaneous PTH (1-34) has been shown to increase BMD in women with GnRH analog-induced estrogen deficiency [<a href="#rid67">67</a>], in premenopausal women taking glucocorticoids [<a href="#rid68">68,69</a>], in premenopausal women with idiopathic osteoporosis [<a href="#rid70">70,71</a>], in women with pregnancy and lactation-associated osteoporosis [<a href="#rid72">72,73</a>], in women with anorexia nervosa [<a href="#rid74">74</a>], and in adults with OI [<a href="#rid22">22,23</a>]. <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> is approved in the United States and other countries for the treatment of women with glucocorticoid-induced osteoporosis. No study has been large enough to document fracture risk reduction. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Parathyroid hormone'</a>.)</p><p>The dosing and administration of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> are the same as in postmenopausal women. This topic is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Overview of approach'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consolidation therapy after </strong><strong>teriparatide</strong> – In <strong>postmenopausal</strong> women, PTH/PTH-related protein (PTHrP) analog treatment is generally followed by antiresorptive therapy to prevent expected bone loss after medication cessation. Available data suggest that the expected BMD trajectory after cessation of anabolic therapy may vary for different types of premenopausal osteoporosis. For premenopausal women with idiopathic osteoporosis, we usually favor consolidation therapy with bisphosphonates after <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> treatment.</p><p></p><p class="bulletIndent2">Few data are available to guide treatment options for <strong>premenopausal</strong> women after cessation of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>One study documented BMD gain in premenopausal women who resumed menses after cessation of both long-acting GnRH analog and <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> therapy [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In another study of 15 premenopausal women with idiopathic osteoporosis and normal gonadal function followed for 2.0±0.6 years after <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> cessation, BMD declined 4.8 percent at the spine and remained stable at the hip [<a href="#rid76">76</a>]. Older age and more robust response to teriparatide tended to predict spine bone loss. These data suggest that women with idiopathic osteoporosis will require antiresorptive treatment to prevent bone loss after discontinuing teriparatide.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In contrast, in a retrospective review of 33 women with severe pregnancy and lactation-associated osteoporosis who were followed for three years, there were no BMD differences between those treated with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> only (n = 20) versus those treated with teriparatide followed by antiresorptive therapy (n = 13) [<a href="#rid77">77</a>]. These data suggest that women with pregnancy and lactation-associated osteoporosis who regain normal menstrual cycles may be able to maintain BMD after the cessation of teriparatide without subsequent antiresorptive therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In premenopausal women with idiopathic osteoporosis, sequential use of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> followed by <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> conferred significant, continued gains in BMD and bone strength [<a href="#rid78">78-80</a>]. In one study in 32 premenopausal women with idiopathic osteoporosis, denosumab treatment for 24 months after discontinuation of teriparatide led to additional average BMD gains of 7±3 percent at spine and 5±3 percent at the total hip [<a href="#rid80">80</a>]. However, no long-term data are available to guide denosumab use in premenopausal women. (See <a class="local">'Other medications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions for use</strong> – <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> has been associated with osteosarcoma in rodent studies. Use of this medication should be avoided in those at increased risk of osteosarcoma (including those with Paget disease, prior radiation, growing bones [open epiphyses], or unexplained elevation in alkaline phosphatase). Thus, this medication should be avoided in those with delayed growth or open epiphyses. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Contraindications/precautions'</a>.)</p><p></p><p class="headingAnchor" id="H4184689001"><span class="h3">Pharmacologic therapy monitoring</span><span class="headingEndMark"> — </span>We remeasure BMD after one year of pharmacologic therapy. The details of pharmacologic treatment monitoring and duration of therapy are reviewed in detail separately for bisphosphonates and <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>. (See  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Monitoring response to therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Practical management issues'</a> and  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H2666740634"><span class="h2">Other medications</span><span class="headingEndMark"> — </span>The following medications have less available evidence to guide treatment in premenopausal women:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Denosumab</strong> – <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a> is a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor that is approved for the treatment of osteoporosis in postmenopausal females and males at high risk for fracture and for the treatment of glucocorticoid-induced osteoporosis in adults at high risk for fracture. Denosumab has been shown to increase BMD in premenopausal women with pregnancy and lactation-associated osteoporosis and in those with idiopathic osteoporosis following <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> treatment [<a href="#rid80">80-82</a>]. </p><p></p><p class="bulletIndent1">Some UpToDate authors prescribe <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for premenopausal patients with severe osteoporosis (eg, fracture affecting a major site, multiple fragility fractures, or fragility fracture in the setting of very low BMD [Z-score ≤-3.0]), either as part of a sequential approach after anabolic therapy or as initial therapy. However, other UpToDate contributors would favor bisphosphonates or <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> over denosumab in this population until more long-term safety data are available, particularly regarding the risk of bone loss after discontinuation of denosumab.</p><p></p><p class="bulletIndent1">In postmenopausal women and men, clinical data show bone loss and increased risk of vertebral fracture after stopping <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>. Another osteoporosis medication (eg, a bisphosphonate) must be administered soon after discontinuing denosumab to prevent rapid bone loss and possible fracture [<a href="#rid83">83</a>]. Nonetheless, optimal regimens for consolidation therapy to prevent bone loss have not been well established. In premenopausal women, it is unknown whether discontinuation of denosumab leads to similar risks of bone loss and fracture. A sequential treatment paradigm including consolidation treatment after discontinuation of denosumab would lengthen a course of treatment, which may not be preferred by younger individuals, including those planning future pregnancy. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Discontinuation or delay of denosumab'</a>.)</p><p></p><p class="bulletIndent1">Animal studies indicate that <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> may cause fetal harm. Prescribing information states that an effective plan for pregnancy prevention is advised during therapy and for at least five months after the last dose. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abaloparatide</strong> – There are no clinical trial data on the efficacy or safety of <a class="drug drug_general" data-topicid="112992" href="/z/d/drug information/112992.html" rel="external">abaloparatide</a> (a PTHrP analog) in premenopausal women. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romosozumab</strong> – There are no clinical trial data on the efficacy or safety of <a class="drug drug_general" data-topicid="120976" href="/z/d/drug information/120976.html" rel="external">romosozumab</a> in premenopausal women. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p></p><p class="headingAnchor" id="H1621028486"><span class="h2">Medications not used in premenopausal women</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SERMs</strong> – SERMs (eg, <a class="drug drug_general" data-topicid="9593" href="/z/d/drug information/9593.html" rel="external">raloxifene</a>) should not be used to treat osteoporosis in menstruating women, as they block estrogen action on bone, leading to further bone loss [<a href="#rid39">39,84</a>]. (See  <a class="medical medical_review" href="/z/d/html/2068.html" rel="external">"Selective estrogen receptor modulators for prevention and treatment of osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcitonin</strong> – There are few published studies on the safety or efficacy of <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">calcitonin</a> in young women. However, in one double-blind study of 120 perimenopausal women treated with 100 international units intranasal calcitonin or placebo spray daily, calcitonin did not confer improvement in BMD or bone markers [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/2025.html" rel="external">"Calcitonin in the prevention and treatment of osteoporosis", section on 'Concerns about the use of calcitonin'</a>.)</p><p></p><p class="headingAnchor" id="H3819672091"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> –<strong> </strong>We suggest against routine screening of premenopausal women for osteoporosis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Bone mineral density (BMD) measurement is recommended for premenopausal women with known secondary causes of osteoporosis or history of a fragility fracture. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Many secondary etiologies of low BMD and/or fragility fracture can be determined based upon history and physical examination. All women with low BMD or fragility fracture should have laboratory testing as part of the evaluation for potential secondary causes of bone loss  (<a class="graphic graphic_table graphicRef53634" href="/z/d/graphic/53634.html" rel="external">table 2</a>). Based on the results of the history, physical examination, and basic laboratory testing, more extensive testing may be indicated. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic approaches</strong> – We assess calcium intake, vitamin D sufficiency, and exercise levels in all premenopausal women with low bone mass. Specific recommendations for calcium and vitamin D intake and supplementation depend on whether the individual has a prior history of kidney stones. Women should engage in daily exercise but may need to limit the extent and intensity to avoid underweight or exercise-induced amenorrhea. (See <a class="local">'Nonpharmacologic approaches for all women'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cause identified</strong> – If a primary cause of bone fragility is identified, management is determined by the underlying condition. (See <a class="local">'Primary cause identified'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary cause identified</strong> – For premenopausal women with a secondary cause of bone loss or bone fragility, treatment should be directed at the underlying cause(s). (See <a class="local">'Treat the underlying cause'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for concomitant pharmacologic treatment </strong>– For women with fracture at major sites (eg, spine or hip) or multiple fragility fractures, we suggest initiating pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Therapy is administered concurrently with addressing the secondary cause of bone loss.</p><p></p><p class="bulletIndent2">For women with advanced bone loss and/or fragility fracture, concomitant pharmacologic treatment also may be warranted when an active secondary cause cannot be readily mitigated and confers high risk for additional short-term bone loss. (See <a class="local">'Indications for concomitant pharmacologic treatment'</a> above and <a class="local">'Choice of therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – After pharmacologic or nonpharmacologic intervention, we remeasure BMD in one to two years. For women undergoing intervention solely targeted to address a secondary cause of bone loss, we reserve pharmacologic therapy for women who experience an interim fragility fracture, have evidence of accelerated bone loss (≥4 to 5 percent BMD loss per year), or have very low BMD (Z-score ≤-3.0) <strong>and</strong> a secondary cause that cannot be adequately addressed. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic low BMD or osteoporosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low BMD</strong> – In premenopausal women with low BMD alone (ie, without history of fractures or known secondary causes for low BMD), pharmacotherapy is generally not indicated. After completing an evaluation for secondary causes, it is reasonable to ensure adequate calcium intake and vitamin D sufficiency and repeat BMD measurement in one to two years. Women with idiopathic low BMD and evidence of ongoing bone loss on repeat BMD measurement should undergo further evaluation for secondary causes of bone loss and, whenever possible, be under the care of a metabolic bone specialist. Women with very low BMD (Z-score ≤-3.0) and ongoing bone loss may warrant pharmacologic therapy. (See <a class="local">'Low BMD for age'</a> above and <a class="local">'Nonpharmacologic approaches for all women'</a> above and <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History of fragility fracture</strong> – For women with idiopathic osteoporosis who have a severe fracture history (eg, fracture at the spine or hip, multiple fragility fractures, or a single fragility fracture in the setting of very low BMD [Z-score ≤-3.0]), we suggest pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'History of fragility fracture'</a> above and <a class="local">'Choice of therapy'</a> above.)</p><p></p><p class="bulletIndent2">For women with idiopathic osteoporosis who do not meet criteria for pharmacologic therapy, we implement nonpharmacologic interventions and repeat BMD measurement in one year. If such women have evidence of ongoing bone loss on repeat BMD measurement, they should undergo more extensive testing for primary and secondary causes and be under the care of a metabolic bone specialist whenever possible. For women with idiopathic osteoporosis, evidence of ongoing bone loss usually warrants pharmacologic therapy. (See <a class="local">'Evaluation'</a> above and <a class="local">'Choice of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of pharmacologic therapy for selected women</strong> – For most premenopausal women with osteoporosis who meet criteria for pharmacologic therapy, we suggest bisphosphonates (eg, <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="10242" href="/z/d/drug information/10242.html" rel="external">risedronate</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Anabolic therapy with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> is an option for selected premenopausal women with a history of vertebral or other major fracture(s), those with fracture in the context of very low BMD (Z-score ≤-3.0), those with very low BMD (Z-score ≤-3.0) <strong>and</strong> ongoing bone loss, and women with known or presumed primary osteoporosis with a history of fragility fracture. (See <a class="local">'Choice of therapy'</a> above and <a class="local">'Antiresorptive therapy with bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent1">Potential short- and long-term risks, as well as potential pregnancy-related risks, should be considered as part of the decision to use bisphosphonates or <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> for the treatment of premenopausal osteoporosis. (See <a class="local">'Antiresorptive therapy with bisphosphonates'</a> above and <a class="local">'Anabolic therapy with teriparatide'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/ (Accessed on July 08, 2019).</li><li><a class="nounderline abstract_t">Jamal SA, Ridout R, Chase C, et al. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res 1999; 14:2143.</a></li><li><a class="nounderline abstract_t">Jones G, Scott F. Low bone mass in premenopausal parous women: identification and the effect of an information and bone density feedback program. J Clin Densitom 1999; 2:109.</a></li><li><a class="nounderline abstract_t">Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551.</a></li><li><a class="nounderline abstract_t">Khan AA, Syed Z. Bone densitometry in premenopausal women: synthesis and review. J Clin Densitom 2004; 7:85.</a></li><li><a class="nounderline abstract_t">Martyn-St James M, Carroll S. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis. J Bone Miner Metab 2010; 28:251.</a></li><li><a class="nounderline abstract_t">Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259.</a></li><li><a class="nounderline abstract_t">MacInnis RJ, Cassar C, Nowson CA, et al. Determinants of bone density in 30- to 65-year-old women: a co-twin study. J Bone Miner Res 2003; 18:1650.</a></li><li><a class="nounderline abstract_t">Bacon L, Stern JS, Keim NL, Van Loan MD. Low bone mass in premenopausal chronic dieting obese women. Eur J Clin Nutr 2004; 58:966.</a></li><li><a class="nounderline abstract_t">Tudor-Locke C, McColl RS. Factors related to variation in premenopausal bone mineral status: a health promotion approach. Osteoporos Int 2000; 11:1.</a></li><li><a class="nounderline abstract_t">Anderson JJ, Rondano PA. Peak bone mass development of females: can young adult women improve their peak bone mass? J Am Coll Nutr 1996; 15:570.</a></li><li><a class="nounderline abstract_t">Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Arch Intern Med 2004; 164:603.</a></li><li><a class="nounderline abstract_t">Niu K, Ahola R, Guo H, et al. Effect of office-based brief high-impact exercise on bone mineral density in healthy premenopausal women: the Sendai Bone Health Concept Study. J Bone Miner Metab 2010; 28:568.</a></li><li><a class="nounderline abstract_t">Peris P, Monegal A, Martínez MA, et al. Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2007; 26:958.</a></li><li><a class="nounderline abstract_t">Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257.</a></li><li><a class="nounderline abstract_t">Winzenberg TM, Shaw K, Fryer J, Jones G. Calcium supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2006; :CD005119.</a></li><li class="breakAll">Institute of Medicine. Report at a Glance, Report Brief: Dietary reference intakes for calcium and vitamin D, released 11/30/2010. http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).</li><li><a class="nounderline abstract_t">Islam MZ, Shamim AA, Viljakainen HT, et al. Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention. Br J Nutr 2010; 104:241.</a></li><li><a class="nounderline abstract_t">Zhao R, Zhao M, Zhang L. Efficiency of jumping exercise in improving bone mineral density among premenopausal women: a meta-analysis. Sports Med 2014; 44:1393.</a></li><li><a class="nounderline abstract_t">Vainionpää A, Korpelainen R, Leppäluoto J, Jämsä T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int 2005; 16:191.</a></li><li><a class="nounderline abstract_t">Lindahl K, Langdahl B, Ljunggren Ö, Kindmark A. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol 2014; 171:R79.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 2014; 124:491.</a></li><li><a class="nounderline abstract_t">Leali PT, Balsano M, Maestretti G, et al. Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab 2017; 14:153.</a></li><li><a class="nounderline abstract_t">Shapiro JR, Lewiecki EM. Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations. J Bone Miner Res 2017; 32:1977.</a></li><li><a class="nounderline abstract_t">Stenson WF, Newberry R, Lorenz R, et al. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005; 165:393.</a></li><li><a class="nounderline abstract_t">Armagan O, Uz T, Tascioglu F, et al. Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis. Clin Rheumatol 2005; 24:239.</a></li><li><a class="nounderline abstract_t">Sategna-Guidetti C, Grosso SB, Grosso S, et al. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther 2000; 14:35.</a></li><li><a class="nounderline abstract_t">Newnham ED, Shepherd SJ, Strauss BJ, et al. Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A 5-year longitudinal study from diagnosis. J Gastroenterol Hepatol 2016; 31:342.</a></li><li><a class="nounderline abstract_t">Zanchetta MB, Longobardi V, Costa F, et al. Impaired Bone Microarchitecture Improves After One Year On Gluten-Free Diet: A Prospective Longitudinal HRpQCT Study in Women With Celiac Disease. J Bone Miner Res 2017; 32:135.</a></li><li><a class="nounderline abstract_t">Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139.</a></li><li><a class="nounderline abstract_t">Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006; 74:90.</a></li><li><a class="nounderline abstract_t">Misra M, Katzman D, Miller KK, et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011; 26:2430.</a></li><li><a class="nounderline abstract_t">Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 2002; 9:236.</a></li><li><a class="nounderline abstract_t">Watts NB, Binkley N, Owens CD, et al. Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life. J Womens Health (Larchmt) 2021; 30:1416.</a></li><li><a class="nounderline abstract_t">Gambacciani M, Cappagli B, Lazzarini V, et al. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 2006; 54:176.</a></li><li><a class="nounderline abstract_t">Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.</a></li><li><a class="nounderline abstract_t">Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.</a></li><li><a class="nounderline abstract_t">Stumpf U, Kostev K, Kyvernitakis J, et al. Incidence of fractures in young women with breast cancer - a retrospective cohort study. J Bone Oncol 2019; 18:100254.</a></li><li><a class="nounderline abstract_t">Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24:675.</a></li><li><a class="nounderline abstract_t">Peris P, Guañabens N, Martínez de Osaba MJ, et al. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 2002; 32:64.</a></li><li><a class="nounderline abstract_t">Peris P, Ruiz-Esquide V, Monegal A, et al. Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities. Clin Exp Rheumatol 2008; 26:986.</a></li><li><a class="nounderline abstract_t">Cohen A, Hostyk J, Baugh EH, et al. Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. Bone 2022; 154:116253.</a></li><li><a class="nounderline abstract_t">Rubin MR, Schussheim DH, Kulak CA, et al. Idiopathic osteoporosis in premenopausal women. Osteoporos Int 2005; 16:526.</a></li><li><a class="nounderline abstract_t">Saarto T, Blomqvist C, Välimäki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15:1341.</a></li><li><a class="nounderline abstract_t">Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955.</a></li><li><a class="nounderline abstract_t">Fuleihan Gel-H, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:3209.</a></li><li><a class="nounderline abstract_t">Greenspan SL, Bhattacharya RK, Sereika SM, et al. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007; 92:131.</a></li><li><a class="nounderline abstract_t">Vehmanen L, Saarto T, Risteli J, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004; 87:181.</a></li><li><a class="nounderline abstract_t">Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008; 26:4289.</a></li><li><a class="nounderline abstract_t">Tauchmanovà L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:81.</a></li><li><a class="nounderline abstract_t">Miller KK, Grieco KA, Mulder J, et al. Effects of risedronate on bone density in anorexia nervosa. J Clin Endocrinol Metab 2004; 89:3903.</a></li><li><a class="nounderline abstract_t">Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90:3179.</a></li><li><a class="nounderline abstract_t">O'Sullivan SM, Grey AB, Singh R, Reid IR. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006; 17:1008.</a></li><li><a class="nounderline abstract_t">Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.</a></li><li><a class="nounderline abstract_t">Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267.</a></li><li><a class="nounderline abstract_t">Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008; 30:1146.</a></li><li><a class="nounderline abstract_t">Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006; 38:613.</a></li><li><a class="nounderline abstract_t">McNicholl DM, Heaney LG. The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf 2010; 5:182.</a></li><li><a class="nounderline abstract_t">Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993; 121:217.</a></li><li><a class="nounderline abstract_t">Patlas N, Golomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60:68.</a></li><li><a class="nounderline abstract_t">Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14:507.</a></li><li><a class="nounderline abstract_t">Illidge TM, Hussey M, Godden CW. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 1996; 8:257.</a></li><li><a class="nounderline abstract_t">Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91:2017.</a></li><li><a class="nounderline abstract_t">Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44:428.</a></li><li><a class="nounderline abstract_t">Sokal A, Elefant E, Leturcq T, et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. Osteoporos Int 2019; 30:221.</a></li><li><a class="nounderline abstract_t">Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004; 19:1742.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998; 280:1067.</a></li><li><a class="nounderline abstract_t">Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.</a></li><li><a class="nounderline abstract_t">Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095.</a></li><li><a class="nounderline abstract_t">Cohen A, Shiau S, Nair N, et al. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial. J Clin Endocrinol Metab 2020; 105:e3540.</a></li><li><a class="nounderline abstract_t">Cohen A, Stein EM, Recker RR, et al. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab 2013; 98:1971.</a></li><li><a class="nounderline abstract_t">Hong N, Kim JE, Lee SJ, et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol (Oxf) 2018; 88:652.</a></li><li><a class="nounderline abstract_t">Lampropoulou-Adamidou K, Trovas G, Triantafyllopoulos IK, et al. Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis. Calcif Tissue Int 2021; 109:554.</a></li><li><a class="nounderline abstract_t">Fazeli PK, Wang IS, Miller KK, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab 2014; 99:1322.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Arnold AL. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 1999; 84:1214.</a></li><li><a class="nounderline abstract_t">Cohen A, Kamanda-Kosseh M, Recker RR, et al. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab 2015; 100:4208.</a></li><li><a class="nounderline abstract_t">Lee S, Hong N, Kim KJ, et al. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis. Calcif Tissue Int 2021; 109:544.</a></li><li><a class="nounderline abstract_t">Agarwal S, Shiau S, Kamanda-Kosseh M, et al. Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT. J Bone Miner Res 2023; 38:35.</a></li><li><a class="nounderline abstract_t">Agarwal S, Shane E, Lang T, et al. Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab. J Clin Endocrinol Metab 2022; 107:e2690.</a></li><li><a class="nounderline abstract_t">Shane E, Shiau S, Recker RR, et al. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab 2022; 107:e1528.</a></li><li><a class="nounderline abstract_t">Sánchez A, Zanchetta MB, Danilowicz K. Two cases of pregnancy- and lactation- associated osteoporosis successfully treated with denosumab. Clin Cases Miner Bone Metab 2016; 13:244.</a></li><li><a class="nounderline abstract_t">Stumpf U, Kraus M, Hadji P. Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis. Osteoporos Int 2021; 32:2383.</a></li><li><a class="nounderline abstract_t">Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2018; 33:190.</a></li><li><a class="nounderline abstract_t">Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78.</a></li><li><a class="nounderline abstract_t">Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 18:629.</a></li></ol></div><div id="topicVersionRevision">Topic 2060 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://www.iscd.org/official-positions/2019-iscd-official-positions-adult/ (Accessed on July 08, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620074" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499969" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Low bone mass in premenopausal parous women: identification and the effect of an information and bone density feedback program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7980966" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology and clinical features of osteoporosis in young individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742892" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bone densitometry in premenopausal women: synthesis and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013013" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11683532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A meta-analysis of the effects of cigarette smoking on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968674" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Determinants of bone density in 30- to 65-year-old women: a co-twin study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15164118" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Low bone mass in premenopausal chronic dieting obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663354" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Factors related to variation in premenopausal bone mineral status: a health promotion approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951733" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Peak bone mass development of females: can young adult women improve their peak bone mass?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037488" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical considerations in premenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20349354" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of office-based brief high-impact exercise on bone mineral density in healthy premenopausal women: the Sendai Bone Health Concept Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941198" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886381" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625624" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Calcium supplementation for improving bone mineral density in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625624" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Calcium supplementation for improving bone mineral density in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193095" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of vitamin D, calcium and multiple micronutrient supplementation on vitamin D and bone status in Bangladeshi premenopausal garment factory workers with hypovitaminosis D: a double-blinded, randomised, placebo-controlled 1-year intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24981245" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficiency of jumping exercise in improving bone mineral density among premenopausal women: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15221206" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24760541" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of osteogenesis imperfecta in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463451" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29263724" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28731215" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hypophosphatasia in Adults: Clinical Assessment and Treatment Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738367" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940557" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632643" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26212198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A 5-year longitudinal study from diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27447366" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impaired Bone Microarchitecture Improves After One Year On Gluten-Free Diet: A Prospective Longitudinal HRpQCT Study in Women With Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699307" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860045" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21698665" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12082359" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34435897" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone Mineral Density Changes Associated With Pregnancy, Lactation, and Medical Treatments in Premenopausal Women and Effects Later in Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16332417" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542321" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747868" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31440445" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Incidence of fractures in young women with breast cancer - a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446340" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12219322" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210860" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34743040" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300364" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic osteoporosis in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193325" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769994" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17047022" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377842" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779616" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247420" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292325" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of risedronate on bone density in anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784715" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758139" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bisphosphonates in pregnancy and lactation-associated osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17663640" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842676" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175968" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Does treatment with bisphosphonates endanger the human pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504613" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bisphosphonate actions: physical chemistry revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19534636" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The safety of bisphosphonate use in pre-menopausal women on corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346538" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of the bisphosphonate, alendronate, on parturition in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440778" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730757" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pharmacovigilance study of alendronate in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8871006" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551739" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059370" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pregnancy outcome following in utero exposure to bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171300" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355570" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9757854" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003959" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Teriparatide or alendronate in glucocorticoid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350340" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876328" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543660" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29389010" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34132853" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24456286" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199756" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26358172" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34037833" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36335582" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35428889" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34849989" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228791" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Two cases of pregnancy- and lactation- associated osteoporosis successfully treated with denosumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34041561" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105841" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558225" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806006" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Salmon calcitonin in the prevention of bone loss at perimenopause.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
